References
- Ruggiero JE, et al. Real-world concordance of clinical practice with ASCO and NCCN guidelines for EGFR/ALK testing in NSCLC. J Clin Oncol. 2017;35(8):212–212.
- Gray SW, et al. Medical oncologists' experiences in using genomic testing for lung and colorectal cancer care. J Oncol Pract. 2017;13(3):e185–e196.
- Schwaederle M, et al. Molecular tumor board: The University of California-San Diego Moores Cancer Center experience. Oncologist. 2014;19(6):631–636.
- Tafe LJ, et al. Implementation of a molecular tumor board: The impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock Medical Center. Oncologist. 2015;20(9):1011–1018.
- Wolff AC, et al. ; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–145.
- Wolff AC, et al. ; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.
- Farhangfar CJ, et al. Utilization of consultative molecular tumor board in community setting. J Clin Oncol. 2017;35 (suppl; abstr 6508).
- Uzilov AV, et al. Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med. 2016;1;8(1):62.